adverse events

An adverse event (AE) is any untoward medical occurrence in a patient or clinical trial subject administered a pharmaceutical product or medical device, which does not necessarily have a causal relationship with the treatment. This concept is formally defined in the International Council for Harmonisation (ICH) Guideline for Good Clinical Practice E6(R2) and is a cornerstone of pharmacovigilance. AEs are distinct from 'side effects,' which are known reactions to a drug. AEs that meet specific criteria, such as being life-threatening or resulting in death, are classified as Serious Adverse Events (SAEs). Within risk management frameworks like ISO 14971 for medical devices, AE data from post-market surveillance is a critical input for updating risk assessments and ensuring ongoing product safety.

Practical application involves a three-step process. Step 1: Establish a Reporting System. Companies implement a pharmacovigilance system compliant with regulations like ICH E2A, creating channels for healthcare professionals and patients to report events. Step 2: Triage and Causality Assessment. A dedicated safety team assesses incoming reports for seriousness and uses standardized methods, like the WHO-UMC system, to evaluate the causal link to the product. Step 3: Risk Mitigation and CAPA. Based on the analysis, firms initiate Corrective and Preventive Actions (CAPA), which can range from updating the product label with new warnings to a product recall. For example, a company identified an unforeseen risk via its AE system, updated its product warning, and successfully reduced the incidence rate by 60%, ensuring regulatory compliance and patient safety.

Taiwanese enterprises face three key challenges. First, under-reporting and resource constraints, as SMEs often lack dedicated staff and healthcare professionals are overburdened. The solution is to implement user-friendly electronic reporting tools and consider outsourcing to expert consultants. Second, regulatory divergence between Taiwan's TFDA and international bodies like the FDA or EMA creates compliance burdens for exporters. This can be mitigated by using RegTech solutions and a global safety database to manage reporting requirements. Third, a lack of in-house expertise for causality assessment. The solution is to establish a cross-functional safety committee with medical experts and adopt standardized assessment algorithms to ensure accurate and objective evaluation.

Winners Consulting specializes in adverse events for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact